Pharmacological basis and new insights of taxifolin: A comprehensive review

被引:160
作者
Das, Abhijit [1 ]
Baidya, Ratna [1 ]
Chakraborty, Tania [1 ]
Samanta, Akash Kumar [1 ]
Roy, Souvik [1 ]
机构
[1] NSHM Knowledge Campus Kolkata, Dept Pharm, 124 BL Saha Rd, Kolkata 700053, W Bengal, India
关键词
Taxifolin; Chemotherapeutics; Antioxidant; Anti-inflammation; Phytochemical; Flavonoids; GROWTH-FACTOR RECEPTOR; ARYL-HYDROCARBON RECEPTOR; FATTY-ACID SYNTHASE; OXIDATIVE STRESS; METABOLIC-ACTIVATION; ANTIOXIDANT ACTIVITY; DIETARY FLAVONOIDS; CELL-CARCINOMA; CANCER CELLS; IN-VITRO;
D O I
10.1016/j.biopha.2021.112004
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The pharmacological characteristics of phytochemicals have prompted a lot of interest in their application in disease management. Due to the high incidence of cancer related mortality and morbidity throughout the world; experiments have concentrated on identifying the anticancer potential of natural substances. Many phytochemicals such as flavonoids and their derivatives produced from food offer a variety of new anti-cancer agents which prevent the cancer progression. Taxifolin, a unique bioactive flavonoid, is a dietary component that has grabbed the interest of dietitians and medicinal chemists due to its wide range of health benefits. It is a powerful antioxidant with a well-documented effect in the prevention of several malignancies in humans. Taxifolin has shown promising inhibitory activity against inflammation, malignancies, microbial infection, oxidative stress, cardiovascular disease, and liver disease. Anti-cancer activity has been shown to be relatively significant than other activities investigated in vitro and in vivo with a little or no side effects to the normal healthy cells. In summary this review offers the synopsis of recent breakthroughs in the use of taxifolin as a cancer treatment, as well as mechanisms of action. However, to develop a medicine for human usage, more study on pharmacokinetic profile, profound molecular mechanisms, and drug safety criteria should be conducted utilizing well-designed randomized clinical trials.
引用
收藏
页数:17
相关论文
共 185 条
[1]   Anti-hyperuricemic effect of taxifolin in cultured hepatocytes and model mice [J].
Adachi, Shin-ichi ;
Nihei, Ken-ichi ;
Ishihara, Yoshiyuki ;
Yoshizawa, Fumiaki ;
Yagasaki, Kazumi .
CYTOTECHNOLOGY, 2017, 69 (02) :329-336
[2]   Effect of taxifolin on development of retinopathy in alloxan-induced diabetic rats [J].
Ahiskali, Ibrahim ;
Pinar, Can Lokman ;
Kiki, Murat ;
Mammadov, Renad ;
Bilgin, Asli Ozbek ;
Hacimuftuoglu, Ahmet ;
Cankaya, Murat ;
Cimen, Ferda Keskin ;
Altuner, Durdu .
CUTANEOUS AND OCULAR TOXICOLOGY, 2019, 38 (03) :227-232
[3]   The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer [J].
Ahmadi, A. ;
Shadboorestan, A. ;
Nabavi, S. F. ;
Setzer, W. N. ;
Nabavi, S. M. .
CURRENT MEDICINAL CHEMISTRY, 2015, 22 (30) :3462-3471
[4]  
Ai Xiaojuan, 2018, Oncotarget, V9, P37589, DOI 10.18632/oncotarget.26428
[5]  
Akinmoladun Afolabi C, 2018, Pathophysiology, V25, P365, DOI 10.1016/j.pathophys.2018.07.002
[6]   Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp [J].
Alfarouk, Khalid O. ;
Stock, Christian-Martin ;
Taylor, Sophie ;
Walsh, Megan ;
Muddathir, Abdel Khalig ;
Verduzco, Daniel ;
Bashir, Adil H. H. ;
Mohammed, Osama Y. ;
Elhassan, Gamal O. ;
Harguindey, Salvador ;
Reshkin, Stephan J. ;
Ibrahim, Muntaser E. ;
Rauch, Cyril .
CANCER CELL INTERNATIONAL, 2015, 15
[7]   Antibacterial and synergy of a flavanonol rhamnoside with antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) [J].
An, J. ;
Zuo, G. Y. ;
Hao, X. Y. ;
Wang, G. C. ;
Li, Z. S. .
PHYTOMEDICINE, 2011, 18 (11) :990-993
[8]   Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids [J].
Androutsopoulos, Vasilis P. ;
Papakyriakou, Athanasios ;
Vourloumis, Dionisios ;
Spandidos, Demetrios A. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (09) :2842-2849
[9]   Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention [J].
Androutsopoulos, Vasilis P. ;
Tsatsakis, Aristidis M. ;
Spandidos, Demetrios A. .
BMC CANCER, 2009, 9
[10]   EMT: 2016 [J].
Angela Nieto, M. ;
Huang, Ruby Yun-Ju ;
Jackson, Rebecca A. ;
Thiery, Jean Paul .
CELL, 2016, 166 (01) :21-45